Group 1 - N必贝特-U (688759) was listed today, opening with a rise of 175.03%, and closing the morning session with a gain of 93.70%, with a trading volume of 26.41 million shares and a turnover of 867 million yuan, resulting in a turnover rate of 56.85% [1][2] - Among the new stocks listed today, N必贝特-U had the smallest increase compared to others, such as N奕材-U which rose by 210.21%, N泰凯英 which increased by 206.13%, and N禾元-U which saw a rise of 202.96% [1][2] - 必贝特 is a biopharmaceutical company focused on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to developing first-in-class drugs and addressing unmet clinical needs [1] Group 2 - The total number of shares issued by the company is 90 million, with an online issuance of 21.6 million shares at a price of 17.78 yuan per share, resulting in a final online subscription rate of 0.04772481% [2] - The total fundraising amount from the initial public offering (IPO) is 1.6 billion yuan, primarily allocated to new drug research and development projects, the establishment of a research and development center in Qingyuan, and the construction of a formulation industrialization base, as well as to supplement working capital [2]

Market Overview - The A-share market experienced a significant rally, with the Shanghai Composite Index breaking the 4000-point mark for the first time since August 19, 2015, marking a historic moment after ten years [1] - As of the midday session, the Shanghai Composite Index rose by 0.21% to 4005.44 points, while the Shenzhen Component Index increased by 0.52% and the ChiNext Index surged by 1.35% [1] Trading Data - The trading volume for the day reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Specific index performances included: - Shanghai Composite Index: 4005.44, up 8.50 points (0.21%), with a trading volume of 588.4 billion yuan [2] - Shenzhen Component Index: 13559.57, up 70.17 points (0.52%), with a trading volume of 761.1 billion yuan [2] - ChiNext Index: 3277.97, up 43.52 points (1.35%), with a trading volume of 360.3 billion yuan [2] Sector Performance - The Fujian sector showed strong performance, with notable stocks such as Pingtan Development (000592) achieving a significant rise [3] - The nuclear power sector was active, with stocks like Dongfang Tantalum Industry (000962) and Antai Technology (000969) showing gains [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligent Equipment (300455) reaching a historical high [3] - The diamond cultivation concept saw a pullback, with stocks like Huifeng Diamond declining over 5% [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the number of new listings in a single day this year [3] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw significant opening gains, with Xi'an Yicai opening up 360% [3][5] - The introduction of these unprofitable hard-tech companies to the Sci-Tech Innovation Board indicates a smoother path for such firms to go public [5]

Core Points - The A-share market experienced a significant rally, with the Shanghai Composite Index surpassing the 4000-point mark for the first time in ten years, closing at 4005.44 points, up 0.21% [1][6] - The trading volume reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Key sectors showing strong performance included Fujian, nuclear power, and commercial aerospace, while coal and precious metals sectors faced declines [3] Market Performance - The Shanghai Composite Index rose by 8.50 points, or 0.21%, with a trading volume of 588.4 billion yuan [2] - The Shenzhen Component Index increased by 70.17 points, or 0.52%, with a trading volume of 761.1 billion yuan [2] - The ChiNext Index saw a rise of 43.52 points, or 1.35%, with a trading volume of 360.3 billion yuan [2] Sector Highlights - The Fujian sector was particularly strong, with stocks like Pingtan Development achieving significant gains [3] - The nuclear power sector was active, with companies like Dongfang Tantalum and Antai Technology showing notable performance [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligence Equipment reaching new historical highs [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the year [4] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw substantial opening gains, with Xi'an Yicai opening up 360% [4][5] - The introduction of these companies signifies a smoother path for unprofitable hard-tech enterprises to enter the market [5]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) aims to deepen comprehensive reforms in the capital market to enhance its inclusiveness, adaptability, attractiveness, and competitiveness, thereby better serving the "14th Five-Year Plan" development goals and the construction of a financial power [1][7]. Group 1: Market Developments - The first batch of new registered companies in the Sci-Tech Innovation Board's growth layer was listed on October 28, marking a significant advancement in the board's reform and development [1]. - Three unprofitable companies, He Yuan Biological-U (688765.SH), Xi'an Yicai-U (688783.SH), and Bibete-U (688759.SH), collectively went public [1]. - As of now, the number of companies in the Sci-Tech Innovation Board's growth layer has reached 35, with a total of 592 listed companies on the board [6]. Group 2: Regulatory and Institutional Support - The CSRC has successfully implemented the "1+6" reform policy since June, which includes the introduction of professional institutional investors and pre-review systems [5]. - The Shanghai Municipal Government is actively collaborating with the CSRC to enhance the operational stability and functionality of the Sci-Tech Innovation Board [5]. - The Shanghai Stock Exchange (SSE) has completed preparations for rules, technology, and market readiness within four months following the reform policy's release [6]. Group 3: Future Plans and Strategic Focus - The CSRC plans to research and formulate strategic tasks and major initiatives for the capital market during the "14th Five-Year Plan" period, focusing on risk prevention, strong regulation, and promoting high-quality development [7]. - The SSE will focus on four key areas: maintaining the "hard technology" positioning, promoting development through reform, enhancing regulatory effectiveness, and prioritizing investor protection [8].

证券时报·数据宝统计显示，公司本次发行总量为9000.00万股，其中，网上发行量为2160.00万股，发行 价格为17.78元/股，网上发行有效申购户数为383.61万户，网上发行最终中签率为0.04772481%。公司首 发募集资金16.00亿元，募集资金主要投向新药研发项目、清远研发中心及制剂产业化基地建设项目、 补充流动资金项目等。（数据宝） （文章来源：证券时报网） N必贝特-U今日上市，开盘价48.90元，上涨175.03%。 必贝特是一家以临床价值为导向、专注于创新药自主研发的生物医药企业。公司聚焦于肿瘤、自身免疫 性疾病、代谢性疾病等重大疾病领域，依托自主研发构建的核心技术平台，持续开发临床急需的全球首 创药物(First-in-Class)和针对未满足临床需求的创新药物。公司秉承"矢志创新，追求更好"的愿景，坚持 自主创新，致力于研发出具有全球自主知识产权、安全、有效的创新药物。 ...

Group 1 - The core point of the news is that three unprofitable companies, Hebao Technology, Xi'an Yicai, and He Yuan Bio, are set to debut on the STAR Market, marking them as the first batch of newly registered companies in the growth tier of the STAR Market [1] - Hebao Technology and Xi'an Yicai opened lower, with both experiencing a decline of 30% from their opening prices, triggering a trading halt [1] - He Yuan Bio opened high but then fell back, showing a decline of over 10% from its opening price [1]

消息面上，10月28日，禾元生物、西安奕材、必贝特三家未盈利公司登陆科创板，成为科创板科创成长层 首批新注册公司。 编辑｜钉钉 | < W | | N奕材-U(688783) | | | | | --- | --- | --- | --- | --- | --- | | | | 10-28 09:32:36 融 成 | | | | | 27.85 | | 额 3.28亿 股本 40.38亿 市盈™ -159 | | | 万得 盘口 | | 19.23 | 223.09% 换 5.43% 市值 1125亿 市净" | 8.94 | | | | | 分时 | 五日 日K 周K | | | 中文 | (0 | | 叠加 | 均价:36.65 | | 盘口 | | 资金 | | 40.00 | 364.04% | | 51 +7 | | | | | | | SE DE | | | | 8.62 | 0.00% 买一 | | | | | | | | | ST M | | | | -22.76 | -364.04% | | 25 1 | | | | 09:15 | 09:30 11:30/13:00 15:00 9:32 ...

(责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇10月28日｜必贝特开盘走低，涨幅近91%，较开盘价跌幅达30%，触发临停。 ...

Core Viewpoint - Bibet has successfully listed on the STAR Market, marking its entry as one of the first newly registered companies in the growth tier of the STAR Market, with a significant opening increase of 175.03% on its first trading day [1] Company Overview - Bibet is a biopharmaceutical company focused on innovative drug development, guided by clinical value, and specializes in major disease areas such as tumors, autoimmune diseases, and metabolic diseases [1] - The company relies on its self-developed core technology platform to continuously develop first-in-class drugs and innovative drugs that meet unmet clinical needs [1] Product Pipeline - Bibet has one approved breakthrough therapy drug, BEBT-908 (injectable hydrochloride ipilimumab), for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) [1] - The company has BEBT-209 in Phase III clinical trials and BEBT-109 has been approved to start Phase III clinical trials, with five products currently in Phase I clinical trials [1] - Additionally, multiple innovative drug products are in preclinical research stages [1]

N奕材、N必贝特涨幅回落，触发临停。 ...